Related references
Note: Only part of the references are listed.Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials
Donald A. Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
Adjuvant therapy of triple negative breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Naked CanScript, an 18-base pair sequence, has tumor cell-specific promoter activity in vivo: Implications for targeted gene therapy
Janet A. Sawicki et al.
CANCER RESEARCH (2010)
Clinicopathological features and treatment strategy for triple-negative breast cancer
Yutaka Yamamoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Luisa Bonilla et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
Yago Nieto et al.
CURRENT OPINION IN ONCOLOGY (2009)
Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
Robert Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Can Women With Early-Stage Breast Cancer Make an Informed Decision for Mastectomy?
E. Dale Collins et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial
Heikki Joensuu et al.
LANCET ONCOLOGY (2009)
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Hyman B. Muss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy:: results of WSG AM-01 trial
O. Gluz et al.
ANNALS OF ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Weekly paclitaxel in the adjuvant treatment of breast cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
Chee-Onn Leong et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
S Rodenhuis et al.
ANNALS OF ONCOLOGY (2006)
Share Paper
